Laropiprant

Jump to: navigation, search
Laropiprant
Laropiprant.png
Identifiers
CAS Number
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC21H19ClFNO4S
Molar mass435.90 g/mol

WikiDoc Resources for Laropiprant

Articles

Most recent articles on Laropiprant

Most cited articles on Laropiprant

Review articles on Laropiprant

Articles on Laropiprant in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Laropiprant

Images of Laropiprant

Photos of Laropiprant

Podcasts & MP3s on Laropiprant

Videos on Laropiprant

Evidence Based Medicine

Cochrane Collaboration on Laropiprant

Bandolier on Laropiprant

TRIP on Laropiprant

Clinical Trials

Ongoing Trials on Laropiprant at Clinical Trials.gov

Trial results on Laropiprant

Clinical Trials on Laropiprant at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Laropiprant

NICE Guidance on Laropiprant

NHS PRODIGY Guidance

FDA on Laropiprant

CDC on Laropiprant

Books

Books on Laropiprant

News

Laropiprant in the news

Be alerted to news on Laropiprant

News trends on Laropiprant

Commentary

Blogs on Laropiprant

Definitions

Definitions of Laropiprant

Patient Resources / Community

Patient resources on Laropiprant

Discussion groups on Laropiprant

Patient Handouts on Laropiprant

Directions to Hospitals Treating Laropiprant

Risk calculators and risk factors for Laropiprant

Healthcare Provider Resources

Symptoms of Laropiprant

Causes & Risk Factors for Laropiprant

Diagnostic studies for Laropiprant

Treatment of Laropiprant

Continuing Medical Education (CME)

CME Programs on Laropiprant

International

Laropiprant en Espanol

Laropiprant en Francais

Business

Laropiprant in the Marketplace

Patents on Laropiprant

Experimental / Informatics

List of terms related to Laropiprant

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

Laropiprant (pINN; codenamed MK-0524A) is an investigational treatment for hypercholesterolemia. It is a prostanoid DP1 receptor antagonist. It will be marketed by Merck & Co. as a combination with niacin and will be sold under the tradenames Cordaptive and Tredaptive.

In October 2008, Merck expanded the THRIVE Trial from 20,000 to 25,000 patients in order to expedite a second bid for FDA approval of its experimental cholesterol drug, MK-0524A. MK-0524A is a combination of niacin and laropiprant, which is aimed at limiting facial flushing associated with niacin. In April 2008 the FDA decided to withhold approval for the experimental drug, deciding to wait until the results of the THRIVE Trial could be analyzed.[1]




Linked-in.jpg